VSTM News and Press, Verastem Inc. From 10/23/25

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that the Company will host a conference call and webcast to discuss its third quarter 2025 financial results and business updates o...

2025-10-20 13:15:03 ET RBC Capital analyst issues OUTPERFORM recommendation for VSTM on October 20, 2025 04:16PM ET. The previous analyst recommendation was Outperform. VSTM was trading at $8.32 at issue of the analyst recommendation. The overall analyst consensus : BUY....

2025-10-20 12:53:02 ET from RBC Capital issued a price target of $13.00 for VSTM on 2025-10-20 16:16:44. The adjusted price target was set to $13.00. At the time of the announcement, VSTM was trading at $8.01. The overall price target consensus is at $9.80 with high pric...

GFH375 resulted in a 41% ORR for patients with heavily pre-treated pancreatic ductal adenocarcinoma (68% had received 2 or more prior lines of therapy) at the 600 mg daily dose At month four, the OS rate was 92.2%; median OS has not been reached 9 1.5% of patients experienced ...

2025-10-07 23:57:48 ET Topline Summary and Update Read the full article on Seeking Alpha For further details see: Verastem: Navigating Critical Steps In Commercialization And Development (Downgrade)

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that its management team is scheduled to participate and present at the following investor conferences in September: Cantor G...

GFH375 demonstrated an overall response rate (ORR) of 68.8% in non-small cell lung cancer (NSCLC) at the recommended Phase 2 dose of 600 mg QD GFH375 demonstrated an ORR of 57.7% in efficacy evaluable patients with NSCLC across all dose levels Mini oral presentation on Sunday, Sep...

2025-08-08 20:55:40 ET Verastem, Inc. (VSTM) Q2 2025 Earnings Conference Call August 07, 2025, 04:30 PM ET Company Participants Daniel Calkins - Chief Financial Officer Daniel W. Paterson - President, CEO & Director Julissa Viana - Vice President of Corporate...

2025-08-08 14:49:44 ET More on Verastem Verastem: The Market Is Ignoring The Progress Verastem: Approval Secured, Moving On To PDAC And KRAS G12D-Related Cancers Verastem Q2 2025 Earnings Preview Verastem Oncology gets FDA fast track status for cancer drug ...

2025-08-07 16:32:39 ET More on Verastem Verastem: The Market Is Ignoring The Progress Verastem: Approval Secured, Moving On To PDAC And KRAS G12D-Related Cancers Verastem Q2 2025 Earnings Preview Verastem Oncology gets FDA fast track status for cancer drug ...